Growth and Characterization of Sodium Salicylate Single Crystal
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
-
Aceclofenac As a Potential Threat to Critically Endangered Vultures in India: a Review Author(S): Pradeep Sharma Source: Journal of Raptor Research, 46(3):314-318
Aceclofenac as a Potential Threat to Critically Endangered Vultures in India: A Review Author(s): Pradeep Sharma Source: Journal of Raptor Research, 46(3):314-318. 2012. Published By: The Raptor Research Foundation DOI: http://dx.doi.org/10.3356/JRR-11-66.1 URL: http://www.bioone.org/doi/full/10.3356/JRR-11-66.1 BioOne (www.bioone.org) is a nonprofit, online aggregation of core research in the biological, ecological, and environmental sciences. BioOne provides a sustainable online platform for over 170 journals and books published by nonprofit societies, associations, museums, institutions, and presses. Your use of this PDF, the BioOne Web site, and all posted and associated content indicates your acceptance of BioOne’s Terms of Use, available at www.bioone.org/ page/terms_of_use. Usage of BioOne content is strictly limited to personal, educational, and non- commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder. BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research. SHORT COMMUNICATIONS J. Raptor Res. 46(3):314–318 E 2012 The Raptor Research Foundation, Inc. ACECLOFENAC AS A POTENTIAL THREAT TO CRITICALLY ENDANGERED VULTURES IN INDIA:AREVIEW PRADEEP SHARMA1 Department of Veterinary Microbiology and Biotechnology, Rajasthan University of Veterinary and Animal Science, Bikaner 334001, Rajasthan, India KEY WORDS: Vultures; Gyps; aceclofenac; diclofenac; India; cations in humans (Kay and Alldred 2003) and marked South Asia; toxicity. analgesic, antiarthritic and antipyretic properties. -
Rationale of Aceclofenac in Management of Pyrexia in Paediatric Practice
ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.11.002112 Avinash Shankar. Biomed J Sci & Tech Res Research Article Open Access Rationale of Aceclofenac in Management of Pyrexia in Paediatric Practice Avinash Shankar*1, Amresh Shankar2 and Anuradha Shankar3 1Postgraduate in Endocrinology & Metabolism (AIIMS Delhi), Chairman National Institute of Health & Research Warisaliganj (Nawada), India 2Aarogyam Punarjeevan Ram Bhawan, India 3Centre for Indigenous Medicine & Research Senior Research Fellow Regional Institute of Ayurveda, India Received: : November 19, 2018; Published: : November 28, 2018 *Corresponding author: Avinash Shankar, Postgraduate in Endocrinology & Metabolism (AIIMS Delhi) Chairman National Institute of Health & Research Warisaliganj (Nawada) Bihar, India Abstract Pyrexia, a complex physiological response triggered by infection or aseptic stimuli causes increase in Prostaglandin E2(PGE2)concentration children with pyrexia of varied origin and to calm the temperature at optimal level various therapeutics are in vogue but attendance of children with antipyreticsin brain and adversity later firing presenting rate of neuronesas morbidity of thermoregulatoryand mortality necessiated centre i.e.an evaluationHypothalamus. of presenting Majority hazardsattendance with at consuming paediatrician antipyretics. chamber are of Objective of Study: Analyse the rationality of Aceclofenac paracetamol combination, as antipyretics in paediatric practice. Material & Methods: Analysis of datasheet of patients admitted with antipyretics adversity at Centre For Children Disease & Research. Result: Children consuming Aceclofenac Sodium Paracetamol presented with grave status of prolonged hypothermia, CNS disturbances like Dizziness, Convulsion, coma in addition to more pronounced other presentation like persistant vomiting, haematemesis, blood dyscariasis, rash, albuminuria than other. Conclusion: Acceclofenac sodium Paracetamol combination must be restricted for paediatrics use considering its dreaded outcome. -
Comparison of Efficacy of Diclofenac Versus Aceclofenac
The Internet Journal of Orthopedic Surgery ISPUB.COM Volume 19 Number 2 Comparison of Efficacy of Diclofenac versus Aceclofenac in Post Operative Pain in Lower limb fractures: a Double blind, Randomized Study V Sharma, B Awasthi, S Rana, S Sharma Citation V Sharma, B Awasthi, S Rana, S Sharma. Comparison of Efficacy of Diclofenac versus Aceclofenac in Post Operative Pain in Lower limb fractures: a Double blind, Randomized Study. The Internet Journal of Orthopedic Surgery. 2012 Volume 19 Number 2. Abstract INTRODUCTION: Providing effective postoperative analgesia is a significant challenge in patients undergoing orthopedic surgery. Non steroidal anti-inflammatory group of drugs is used mostly to achieve it. This clinical study was done to investigate efficacy of Injectable Aceclofenac over inj. Diclofenac in patients with severe postoperative pain in lower limb fractures. METHODS: 100 patients (aged 18-60 yr) of lower limb fractures were enrolled as per inclusion criteria . They were randomly assigned to Group A or Group B (50 patients each ) .Severe pain was postoperative pain 7 or >7 on Numerical Rating Scale. For postoperative analgesia, in Group A Inj. Aceclofenac ( 12 hourly) and in Group B Inj. Diclofenac (8 hourly) was given . To abort pain in case of no relief Inj. Tramadol was given. Decrease in Numerical Rating Scale score in either the group and associated adverse effects were noted . Patients’ overall subjective response to therapy was rated as poor , fair , good or excellent . RESULTS: After treatment at 10 min. only the mean pain score had 47.8% fall in Group A and 40.3% in Group B. -
Penetrating Pharmaceutical Foam Eindringender Pharmazeutischer Schaum Mousse Pharmaceutique Pénétrante
(19) TZZ _T (11) EP 2 422 768 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 31/196 (2006.01) 15.04.2015 Bulletin 2015/16 A61K 31/167 (2006.01) A61Q 19/00 (2006.01) A61K 31/496 (2006.01) A61K 9/107 (2006.01) (2006.01) (2006.01) (21) Application number: 11190124.5 A61K 8/04 A61K 8/42 A61K 8/365 (2006.01) (22) Date of filing: 20.08.2004 (54) Penetrating pharmaceutical foam Eindringender pharmazeutischer Schaum Mousse pharmaceutique pénétrante (84) Designated Contracting States: • Raymond C Rowe, Paul J Sheskey and Marian E AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Quinn (Ed.): "Decyl oleate", Handbook of HU IE IT LI LU MC NL PL PT RO SE SI SK TR Pharmaceutical Excipients , 2011, pages 1-4, XP002666037, Retrieved from the Internet: URL: (30) Priority: 25.08.2003 US 497648 P http://www.medicinescomplete.com/mc/ex cipients/current/EXP-TD-c40-mn0001.htm?q=d (43) Date of publication of application: ecyloleate&t=search&ss=text&p=1#_hit 29.02.2012 Bulletin 2012/09 [retrieved on 2011-12-19] • Raymond C Rowe, Paul J Sheskey and Marian E (62) Document number(s) of the earlier application(s) in Quinn(Ed.): "Glyceryl Monooleate", Handbookof accordance with Art. 76 EPC: Pharmaceutical Excipients , 2011, pages 1-5, 04769356.9 / 1 663 148 XP002666038, Retrieved from the Internet: URL: http://www.medicinescomplete.com/mc/ex (73) Proprietor: Foamix Pharmaceuticals Ltd. -
Chemical UVR Absorbers
Chemical UVR Absorbers The names given in bold and used Diisopropyl methyl cinnamate Glyceryl ethyihexanoate dimethoxy- throughout this handbook are those of Empirical formula: cinnamate the International Nomenclature of C 6H22O2 Chemical names. Cosmetic Ingredients. Glyceryl octanoate dimethoxycinnamate; Chemical names: 2-propenoic acid, 3-(4-methoxyphenyl)-, 2-Propenoic acid, 3-12,4bis(1 diester with 1 ,3-dihydroxy-2-(2-ethyl-1 - methylethyphenyl-methyl ester; 2,5- oxohexyl)oxypropane diisopropyl methyl cinnamate _ lsoamyl-para-methoxycinnamate Ethyihexyl methoxycinnamate Empirical formula: Empirical formula: C151-12003 C 8H26O3 Chemical names: Cinnamates Chemical names: Amyl4-methoxycinnamate; isopentyl-4- 2-Ethylhexyl-4-methoxycin nam ate; methoxycinnamate; isopenlyl-para- Cinoxate 2-ethyl-hexyl-para-methoxycinnamate; methoxy-cinnamate; 3-(4-methoxyphenyl)- Empirical formula: para-methoxycinnamic acid, 2-ethylhexyl 2-propenoic acid, isopentyl ester Ci4HieO4 ester; 3-(4-methoxyphenyl)-2-propenoic acid, 2-ethylhexyl ester; octinoxate; octyl Trade names: Chemical names: methoxycinnamate; 2-propenoic acid, 3- Neo Heliopan type E 1000; Solarum AMC 2- Ethoxyothyl-para-methoxyci n nam ate; (4-methoxyphenyl)-2-ethylhexyl ester 2-propenoic acid, 3-(4-methoxyphery- para-A minobenzoic acids (PA BAs) 2-ethoxyethyl ester; 2-ethoxyethyl-4- Trade names: methoxycinnamate AEC Octyl Methoxycinnamate; Escalol Amyl dimethyl FABA 557; Eusolex 2292; Heliosol 3; Empirical formula: Trade names: Jeescreen OMC; Katoscreen OMC; Nec C14H21 NO2 Giv Tan F; Phiasol -
S1 Table. List of Medications Analyzed in Present Study Drug
S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine -
How to Use This Guide Dielectric Constant Table
Dielectric Constant Table.xls Dielectric Constant Table Dielectric Constant (k) is a number relating the ability of a material to carry alternating current to the ability of vacuum to carry alternating current. The capacitance created by the presence of the material is directly related to the Dielectric Constant of the material. Alphabetic Table A B C D Knowing the Dielectric Constant (k) of a material is needed to properly E F G H design and apply instruments such as level controls using radar, RF I J K L admittance, or capacitance technologies. There are also analytical M N O P reasons to know the (k) of a material. Q R S T U V W X How to use this guide Y Z # CLIPPER CONTROLS has compiled an extensive list of products with Dielectric Constants. Many of these Dielectric Constants are given at specific temperatures. If your product's temperature is significantly different from those listed there is a good chance that the Dielectric Constant may be different from the values listed. The products in this reference are listed in alphabetical order and are grouped in sections by the first letter of their name. Proper chemical names were used, and any trade names are the trademark of their respective owners. If you know the correct spelling of the name of the product you wish to review then use the "Search" feature on the web browser to locate the name in the list. You may also click on the letter from the alphabetical table to go directly to the beginning of that alphabetic section. -
Celofen® Aceclofenac
Only for the use of Medical Professionals Celofen® Aceclofenac Presentation Celofen® 100mg Tablets: Round, light pink colored film coated tablet, one side embossed with 'ACI' and other side with a break line. Each tablet contains 100mg Aceclofenac BP. Description Celofen® is a non-steroidal agent with anti-inflammatory and analgesic properties. Its mechanism of action is largely based on inhibition of prostaglandin synthesis. Celofen® is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandins. Indications & uses Celofen® is indicated in relieving pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Dosage & administration Adults: The maximum recommended dose is 200mg daily, taken as two separate 100mg doses, one tablet in the morning and one in the evening. Children: There is no clinical data on the use of Aceclofenac in children. Elderly: The pharmacokinetics of Aceclofenac are not altered in elderly patients, therefore it is not considered necessary to modify the dose and dose frequency. Renal insufficiency: There is no evidence that the dosage of Aceclofenac needs to be modified in patients with mild renal impairment. Hepatic insufficiency: The dose of Aceclofenac should be reduced in patients with hepatic impairment. An initial daily dose of 100mg should be administered. Contraindications, warnings, etc. Contraindications: Aceclofenac is contraindicated in patients previously sensitive to Aceclofenac or aspirin or other NSAIDs. It should not be administered to patients with active or suspected peptic ulcer or gastrointestinal bleeding and moderate to severe renal impairment. Precautions: Aceclofenac should be administered with caution to patients with symptoms indicative of gastrointestinal disorders, with a history of peptic ulceration, ulcerative colitis, Crohn's disease, hepatic porphyria, and coagulation disorders. -
Prescribing Pattern of Nsaids in Orthopedic Department of Dhaka Medical College Hospital Rahman Ka1 , Kamal Ahmm2, Akhter S 3, Khatun K 4, Afroz R5, Akther T6
PRESCRIBING PATTERN OF NSAIDS IN ORTHOPEDIC DEPARTMENT OF DHAKA MEDICAL COLLEGE HOSPITAL RAHMAN KA1 , KAMAL AHMM2, AKHTER S 3, KHATUN K 4, AFROZ R5, AKTHER T6 Abstract Context : Drug therapy is the most commonly used method in disease treatment in general practice. The pattern of drug prescription are often inappropriate and need for registration of these patterns is essentian in an effort to improve prescribing standard. Nonsteroidal anti- inflammatory drugs (NSAIDs) are a drug class that groups together drugs that provide analgesic (pain-killing) and antipyretic (fever-reliefing) effects, and, in higher doses, anti-inflammatory effects. Non steroidal anti inflammatory drugs are the most common drugs prescribed in the world over specially in the orthopedic department. The study of prescribing pattern of NSAIDs in the orthopedic department was conducted to monitor, evaluate and if necessary suggest modification in the prescribing behavior of the medical practitioner to make it rational and cost effective. Material and Methods: The present study was performed on 300 (Three hundred) prescriptions from both admitted and outpatients (OPD) of the orthopedic department of Dhaka Medical College Hospital, Dhaka. The check list type of data was collected with prior permission from the concern department and the authority. The study was cross sectional analytical type and was conducted in the department of Pharmacology, Dhaka Medical College, Dhaka, from July 2010 to June 2011. Result : In case of OPD patients most common NSAIDs prescribed to the patients were aceclofenac (44.7%); followed by diclofenac (23.3%). Other NSAIDs were naproxen, ketorolac and ibuprofen 8%, 15.3% and 5.4% respectively. -
Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies -
Quantum Chemical Calculations and Molecular Docking Studies of Some NSAID Drugs (Aceclofenac, Salicylic Acid, and Piroxicam) As 1PGE Inhibitors
Hindawi Publishing Corporation International Journal of Spectroscopy Volume 2016, Article ID 5281636, 7 pages http://dx.doi.org/10.1155/2016/5281636 Research Article Quantum Chemical Calculations and Molecular Docking Studies of Some NSAID Drugs (Aceclofenac, Salicylic Acid, and Piroxicam) as 1PGE Inhibitors S. Suresh,1,2 Sethu Gunasekaran,3 and Shanmugam Srinivasan2 1 Department of Physics, Dr. M.G.R. Educational and Research Institute University, Chennai, India 2Department of Physics, Presidency College, Chennai, India 3Research and Development Center, St. Peter’s University, Chennai, India Correspondence should be addressed to S. Suresh; [email protected] Received 6 May 2016; Accepted 10 August 2016 Academic Editor: Soni Mishra Copyright © 2016 S. Suresh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The molecular structure of the three compounds Aceclofenac (I), Salicylic Acid (II), and Piroxicam (III) has been determined using Gaussian 03W program with B3LYP method using 6-311++G (d,p) basis set calculations. The molecular structures were fully optimized with atomic numbering scheme adopted in the study. To understand the mode of binding and molecular interaction, the docking studies of compounds Aceclofenac (I), Salicylic Acid (II), and Piroxicam (III) have been carried out with prostaglandin H2 synthase-1 (1PGE) as target using induced fit docking. The molecular docking results show that the interactions and energy for Aceclofenac, Salicylic Acid, and Piroxicam show the best results when docked with prostaglandin H2 synthase-1 (1PGE). The hydrogen bonding interactions of compound I (Aceclofenac) are prominent with Arginine moiety, those of compound II (Salicylic Acid) are prominent with Tyrosine and Serine moieties, and compound III (Piroxicam) shows such interaction with Tyrosine and Arginine moieties.